Author
Listed:
- Ellen Rafferty
(University of Alberta
Institute of Health Economics)
- Mike Paulden
(University of Alberta)
- Sarah A. Buchan
(Public Health Ontario
University of Toronto)
- Joan L. Robinson
(University of Alberta)
- Julie A. Bettinger
(BC Children’s Hospital and University of British Columbia)
- Manoj Kumar
(University of Alberta)
- Lawrence W. Svenson
(University of Alberta
Alberta Health
University of Alberta
University of Calgary)
- Shannon E. MacDonald
(University of Alberta
University of Alberta)
Abstract
Background Respiratory syncytial virus (RSV) is a major cause of acute respiratory infection (ARI), with high morbidity and mortality worldwide. RSV costing and burden estimates can highlight the potential benefits of future vaccination programs and are essential for economic evaluations. Objective We aimed to determine RSV healthcare costs across age groups and the overall disease burden of medically attended RSV in Canada. Methods We conducted a retrospective case–control study to estimate the attributable healthcare costs per RSV case in Alberta. We used two case definitions to capture diversity in case severity: laboratory-confirmed RSV and ARI attributable to RSV. Matching occurred on five criteria: (1) age, (2) urban/rural status, (3) sex, (4) prematurity and (5) Charlson Comorbidity Index score. We calculated the age-specific burden of medically attended RSV in Canada from 2010 to 2019 by multiplying the weekly age-specific incidence of medically attended ARI with the RSV positivity rate. Results Costs per laboratory-confirmed RSV case were (in Canadian dollars [CAD], year 2020 values) $CAD12,713 and 40,028 in the first 30 and 365 days following diagnosis, respectively, whereas a case of ARI potentially attributable to RSV cost $CAD316 and 915, in 30 and 365 days, respectively. Older (aged ≥ 65 years) and younger (aged
Suggested Citation
Ellen Rafferty & Mike Paulden & Sarah A. Buchan & Joan L. Robinson & Julie A. Bettinger & Manoj Kumar & Lawrence W. Svenson & Shannon E. MacDonald, 2022.
"Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups,"
PharmacoEconomics, Springer, vol. 40(6), pages 633-645, June.
Handle:
RePEc:spr:pharme:v:40:y:2022:i:6:d:10.1007_s40273-022-01142-w
DOI: 10.1007/s40273-022-01142-w
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:40:y:2022:i:6:d:10.1007_s40273-022-01142-w. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.